Chemotherapy Induced Neutropenia (CIN) Treatment Market Report, 2024-2032
Chemotherapy Induced Neutropenia (CIN) Treatment Market Report, 2024-2032

Chemotherapy Induced Neutropenia (CIN) Treatment Market Share, Size, Trends, Industry Analysis Report, by Treatment (Antibiotic Therapy, Granulocyte Colony-Stimulating Factor Therapy, Granulocyte Transfusion, and Others), Distribution Channel; By Region; Segment Forecast, 2024- 2032

  • Published Date:Mar-2024
  • Pages: 114
  • Format: PDF
  • Report ID: PM4799
  • Base Year: 2023
  • Historical Data: 2019-2022

Report Outlook

Global chemotherapy induced neutropenia (CIN) treatment market size was valued at USD 580.79 million in 2023. The market is anticipated to grow from USD 597.23 million in 2024 to USD 775.84 million by 2032, exhibiting the CAGR of 3.3% during the forecast period.

Market Overview

Chemotherapy-Induced Neutropenia (CIN) stands as the primary dose-limiting toxicity observed in cancer patients undergoing chemotherapy treatment. Symptoms commonly associated with Chemotherapy-Induced Neutropenia encompass sore throat, mouth sores or toothaches, abdominal discomfort, chills or perspiration, and pain in the anal region. Several key factors contribute to the development of Chemotherapy-Induced Neutropenia, including advanced age, female gender, diminished performance status, bone marrow involvement, elevated LDH levels, decreased lymphocyte counts, use of high-risk chemotherapy regimens, and albumin levels below 3.5 G/Dl.

Neutropenia resulting from chemotherapy has become a prevalent side effect of cancer treatments. The increased utilization of chemotherapy in cancer therapy and the availability of advanced diagnostic techniques for identifying chemotherapy-induced neutropenia have led to a notable rise in diagnosed cases of chemotherapy-induced neutropenia (CIN) over the past decade. Research indicates that certain types of chemotherapies, such as alkylating agents and antimetabolites, are more commonly associated with chemotherapy-induced neutropenia.

Chemotherapy Induced Neutropenia (CIN) Treatment Market Size

To Understand More About this Research: Request a Free Sample Report

  • For instance, as per the NCBI, in 2022, drug-induced neutropenia was reported at a frequency ranging from 1.6 to 9.2 cases per million in Europe.

Patient factors, including age and gender, may also influence the development of chemotherapy-induced neutropenia. According to NCBI, individuals around the age of 60 are most affected by chemotherapy-induced neutropenia. Hence, it is imperative for physicians to be knowledgeable about the risk factors linked to chemotherapy-induced neutropenia to deliver optimal care to patients.

Additionally, research and development efforts focus on developing innovative treatment modalities aimed at improving outcomes for cancer patients undergoing chemotherapy. This includes the development of novel drugs, biologics, and supportive care interventions specifically targeting neutropenia induced by chemotherapy.

Research and development initiatives in the field of oncology aim to advance personalized medicine approaches, tailoring treatments to individual patients based on their genetic makeup, tumor characteristics, and other factors. This can lead to more effective and targeted therapies for managing chemotherapy-induced neutropenia while minimizing side effects.

Chemotherapy Induced Neutropenia (CIN) Treatmen

Growth Factors

Rising cases of cancer and increasing use of chemotherapy as treatment option

The rising cases of cancer and the increasing use of chemotherapy as a treatment option are significant trends in modern healthcare. Several factors contribute to the increase in cancer cases, including population aging, environmental factors, lifestyle choices such as smoking and poor diet, and improved detection methods. Chemotherapy, along with surgery and radiation therapy, is one of the primary treatment options for cancer. It involves the use of powerful drugs to kill cancer cells or inhibit their growth. Chemotherapy can be administered orally or intravenously and may be used alone or in combination with other treatments depending on the type and stage of cancer.

Despite its effectiveness in killing cancer cells, chemotherapy often comes with side effects due to its impact on healthy cells in the body. These side effects can include nausea, vomiting, hair loss, fatigue, and weakened immune system, among others. However, advancements in medical research and technology have led to the development of targeted therapies and personalized medicine, which aim to minimize side effects and improve treatment outcomes. Additionally, ongoing research continues to explore new treatment approaches, including immunotherapy, gene therapy, and precision medicine, which hold promise for more effective and tailored cancer treatments in the future. Nonetheless, chemotherapy remains a cornerstone of cancer treatment and will likely continue to be used extensively as part of multidisciplinary approaches to combat this disease.

Rising likelihood of chemotherapy induced neutropenia

Chemotherapy-induced neutropenia refers to a condition where the white blood cell count, specifically the neutrophil count, drops to dangerously low levels due to the effects of chemotherapy. Neutrophils are a type of white blood cell crucial for fighting off infections. When their levels decrease significantly, it can increase the risk of infections, which can be life-threatening. As chemotherapy becomes a more common treatment option for various types of cancers, more individuals are exposed to the risk of chemotherapy-induced neutropenia.

Some cancer treatments involve more intensive chemotherapy regimens, which can have a higher likelihood of causing neutropenia compared to milder treatments. Older individuals are more likely to develop neutropenia as a result of chemotherapy. Age-related changes in the bone marrow and immune system can increase susceptibility to this condition.

Patients with pre-existing medical conditions or compromised immune systems may be more susceptible to chemotherapy-induced neutropenia. In some cases, cancer cells may become resistant to certain chemotherapy drugs, requiring higher doses or more aggressive treatment regimens, which can increase the risk of neutropenia.

Restraining Factors

High cost of treatment and stringent regulatory policies

The high costs associated with chemotherapy-induced neutropenia (CIN) treatment and stringent regulations governing product approvals can indeed pose significant challenges during the forecast period. Chemotherapy treatments, including medications to manage CIN such as granulocyte colony-stimulating factors (G-CSFs), can be expensive.

These costs may include not only the price of the drugs themselves but also hospitalization, monitoring, and supportive care. For many patients, especially those without adequate insurance coverage, these expenses can be prohibitive and may impact their ability to access necessary treatment.

Regulatory agencies impose stringent requirements for the approval of medications and therapies, including those used to manage CIN. These requirements are in place to ensure the safety, efficacy, and quality of treatments. However, navigating the regulatory process can be time-consuming and costly for pharmaceutical companies, leading to delays in bringing new treatments to market. Additionally, stringent regulations may limit the availability of certain treatments or require extensive clinical trials, further adding to the time and cost of development.

Report Segmentation

The market is primarily segmented based on treatment type, distribution channel, and region.

By Treatment Type

By Distribution Channel

By Region

  • Antibiotic Therapy
  • Granulocyte Colony-Stimulating Factor Therapy (G-CSF)
  • Granulocyte Transfusion
  • Others 
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
  • North America (U.S., Canada)
  • Europe (France, Germany, UK, Italy, Netherlands, Spain, Russia)
  • Asia Pacific (Japan, China, India, Malaysia, Indonesia. South Korea)
  • Latin America (Brazil, Mexico, Argentina)
  • Middle East & Africa (Saudi Arabia, UAE, Israel, South Africa)

To Understand the Scope of this Report: Speak to Analyst

By Treatment Type Insights

Granulocyte colony-stimulating factor therapy (G-CSF) segment accounted for the largest market share in 2023

G-CSF segment accounted for the largest share, and the dominance of the granulocyte colony-stimulating factor therapy (G-CSF) segment reflects the significance of this treatment modality in managing neutropenia induced by chemotherapy. Granulocyte colony-stimulating factors are a class of drugs that stimulate the production of white blood cells, specifically neutrophils, thereby helping to prevent or reduce the severity of neutropenia and associated complications.

G-CSF therapy has demonstrated efficacy in reducing the duration and severity of neutropenia in patients undergoing chemotherapy. By stimulating the production of neutrophils, G-CSF helps to maintain the body's ability to fight off infections, reducing the risk of serious complications. G-CSF therapy has been widely adopted as a standard prophylactic treatment for patients at high risk of developing neutropenia during chemotherapy.

 It is recommended in clinical practice guidelines for various types of cancer and chemotherapy regimens, contributing to its widespread use. The prominence of the G-CSF therapy segment underscores its importance in the management of chemotherapy-induced neutropenia and highlights the continued demand for effective prophylactic treatments in this patient population.

By Distribution Channel Insights

Hospital pharmacies segment held the majority revenue share in 2023

Hospital pharmacies segment held the majority share. Hospital pharmacies often have access to a wide range of specialty medications, including those used to manage chemotherapy-induced neutropenia. These medications may include granulocyte colony-stimulating factors (G-CSFs) and other supportive care drugs that are commonly administered in a hospital setting.

Hospital pharmacies are closely integrated with oncology departments and cancer treatment centers, facilitating seamless coordination of care for patients undergoing chemotherapy. Pharmacists in these settings play a key role in medication management, ensuring that patients receive appropriate doses of CIN treatments and monitoring for potential drug interactions or adverse effects.

Chemotherapy Induced Neutropenia (CIN) Treatmen Seg

Regional Insights

North America dominated the global market in 2023

The North America region dominated the global chemotherapy induced neutropenia (CIN) treatment market with noteworthy share. North America boasts a well-developed healthcare infrastructure with advanced medical facilities, access to cutting-edge technologies, and a highly skilled workforce. This facilitates the diagnosis, treatment, and management of cancer and its complications, including chemotherapy-induced neutropenia.

North America has a relatively high incidence of cancer compared to other regions, contributing to a larger patient population requiring chemotherapy and, consequently, CIN treatment. Factors such as lifestyle choices, environmental factors, and an aging population contribute to the prevalence of cancer in the region. The region is home to numerous pharmaceutical companies, research institutions, and academic centers at the forefront of cancer research. This fosters innovation in the development of new treatments and therapies for chemotherapy-induced neutropenia, driving market growth.

APAC expected to grow at the rapid pace. With a swiftly expanding population, the region experiences an increasing incidence of cancer attributed to lifestyle shifts and an aging demographic. This expanding patient base drives significant demand for CIN management, consequently bolstering overall market growth in the region.

Moreover, rising cases of breast cancer patients in region frequently encounter instances of chemotherapy-induced neutropenia. These patients often undergo regimens containing docetaxel or dose-dense chemotherapy. A study conducted by Vanderbilt University School of Medicine in Nashville revealed that individuals receiving dose-dense chemotherapy were at a higher risk of experiencing severe neutropenia.

Chemotherapy Induced Neutropenia (CIN) Treatmen Reg

Key Market Players & Competitive Insights

The chemotherapy induced neutropenia treatment market exhibits fragmentation and is poised to face competition owing to the presence of numerous players. Key companies are engaging in competition across several fronts, including enhancing product effectiveness, integrating novel active ingredients into treatments, conducting robust marketing initiatives, and providing competitive pricing to consumers. Additionally, firms are prioritizing strategic partnerships and collaborations to broaden their market footprint and reach a broader customer demographic.

Some of the major players operating in the global market include:

  • AbbVie Inc. (Allergan PLC)
  • Aurobindo Pharma
  • Coherus BioSciences
  • GlaxoSmithKline PLC.
  • Lupin, G1 Therapeutics, Inc.
  • Merck & Co., Inc.
  • Novartis AG.
  • Spectrum Pharmaceuticals

Recent Developments in the Industry

  • In March 2023, Coherus BioSciences obtained approval from the U.S. FDA for Udencya, a biosimilar version of pegfilgrastim used in the treatment of febrile neutropenia induced by chemotherapy.
  • In September 2022, Spectrum Pharmaceuticals received approval from the FDA for its ROLVEDON (eflapegrastim-xnst) injection. This medication aims to reduce the occurrence of infection, particularly febrile neutropenia, in adult patients with non-myeloid malignancies undergoing myelosuppressive anti-cancer treatments linked to a clinically notable incidence of febrile neutropenia.

Report Coverage

The chemotherapy induced neutropenia treatment market report emphasizes on key regions across the globe to provide better understanding of the product to the users. Also, the report provides market insights into recent developments, trends and analyzes the technologies that are gaining traction around the globe. Furthermore, the report covers in-depth qualitative analysis pertaining to various paradigm shifts associated with the transformation of these solutions.

The report provides detailed analysis of the market while focusing on various key aspects such as competitive analysis, treatment type, distribution channel, and their futuristic growth opportunities.

Chemotherapy Induced Neutropenia Treatment Market Report Scope

Report Attributes


Market size value in 2024

USD 597.23 million

Revenue forecast in 2032

USD 775.84 million


3.3% from 2024 – 2032

Base year


Historical data

2019 – 2022

Forecast period

2024 – 2032

Quantitative units

Revenue in USD million and CAGR from 2024 to 2032

Segments covered

  • By Treatment Type
  • By Distribution Channel
  • By Region

Regional scope

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East & Africa

Competitive Landscape

  • Chemotherapy Induced Neutropenia Treatment Market Share Analysis (2023)
  • Company Profiles/Industry participants profiling includes company overview, financial information, product/service benchmarking, and recent developments

Report Format

  • PDF + Excel


Report customization as per your requirements with respect to countries, region and segmentation.


The Chemotherapy Induced Neutropenia (CIN) Treatment Market report covering key segments are treatment type, distribution channel, and region.

The global chemotherapy induced neutropenia treatment market size is expected to reach USD 775.84 million by 2032

Chemotherapy induced neutropenia (CIN) treatment market exhibiting the CAGR of 3.3% during the forecast period.

North America is leading the global market

key driving factors in Chemotherapy Induced Neutropenia (CIN) Treatment Market are Rising cases of cancer and increasing use of chemotherapy as treatment option